Where I see patients (1)
Selected research
-
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Cell reports. Medicine
-
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.
Cancer research communications
-
Creation of a sustainable longitudinal women in Leadership Development (WILD) curriculum focused on graduate medical education trainees.
BMC medical education
Clinical trials
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lun...
according to RECIST v 1.1 by investigator assessment from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss ...
Recruiting